Psoriatic arthritis: the role of self-reported non-adherence, non-trough drug levels, immunogenicity and conventional synthetic DMARD co-therapy in adalimumab and etanercept response.
Philippa D K CurryAndrew P MorrisMeghna JaniGabriela Arredondo Hector ChinoyRichard B WarrenJames Bluettnull nullPublished in: Rheumatology advances in practice (2024)
Although both were associated with reduced response, the objectively measured non-trough drug levels showed more significant associations with drug response than self-reported non-adherence measures.